Press Releases



    • JAN 31 2018

    ONC201 Trial Begins at NYU for Children with H3 K27M Mutant Glioma

    Philadelphia, PA (January 31, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation. The trial, which will treat patients with recurrent high-grade gliomas, including glioblastoma and diffuse intrinsic

    • JAN 16 2018

    Oncoceutics and Frontida BioPharm Announce Product Development and Commercialization Partnership

    Philadelphia, PA (January 16, 2018) –Oncoceutics Inc. and Frontida BioPharm, Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201, Oncoceutics’ lead molecule. ONC201 is an antagonist of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) and

    • JAN 08 2018

    Oncoceutics Extends IP Coverage to Japan with New Patent Covering All Cancers

     Oncoceutics Extends IP Coverage to Japan with New Patent Covering All Cancers Philadelphia, PA (January 8, 2018) – Oncoceutics, Inc. announced that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers,

    • DEC 19 2017

    Oncoceutics Extends Composition of Matter Patent Portfolio to ONC212

    Philadelphia, PA (December 19, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics’ lead compound ONC201. ONC212 is one of the lead follow-on compounds in the company’s development pipeline